CDER’s latest proposal to withdraw the accelerated approval of Makena (HPC) was based mostly upon a big randomized demo that failed to verify the advantage of this drug to newborns or cut down the chance of PTB. In earning the decision to suggest Makena’s withdrawal, CDER also reviewed success from prior reports of progestins (HPC together wi… Read More